Please login to the form below

Not currently logged in
Email:
Password:

CXA-201

This page shows the latest CXA-201 news and features for those working in and with pharma, biotech and healthcare.

Cubist publishes positive data on novel antibiotic

Cubist publishes positive data on novel antibiotic

combination CXA-201 (ceftolozane/tazobactam) for complicated urinary tract and intra-abdominal infections in the US in April. ... CXA-201 is also due to be filed in Europe later this year and is in phase III testing for hospital-acquired bacterial

Latest news

  • Cubist posts positive phase III antibiotic data Cubist posts positive phase III antibiotic data

    CXA-201 combines a novel cephalosporin (ceftolozane) with a well-established beta-lactamase inhibitor and is designed to tackle Gram-negative bacterial infections. ... Data from the latest study demonstrated that CXA-201 was within 10 per cent of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics